The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Diversified Royalty Acquired the Trademarks and Some Other Intellectual Property Used by Cheba Hut Franchising for $36M and Additional Consideration; Adds Ninth Royalty Stream and Second Based in U.S.

Fintel reports that on June 17, 2025, Goldman Sachs downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Fintel reports that on June 17, 2025, Morgan Stanley downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.